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We previously showed that reduced infectivity of HIV with incompletely processed capsid-spacer
protein 1 (CA-SP1) is rescued by cellular activation or increased expression of HSP90AB1, a member of
the cytosolic heat shock protein 90 family. Here we show that HSP90AB1 is present in HIV virions and
that HSP90AB1, but not nonfunctional mutated HSP90AB1E42AþD88A, restores infectivity to HIV with
mutations in CA that alter core stability. Further, the CA mutants were hypersensitive to pharmaco-
logical inhibition of HSP90AB1. In agreement with Roesch et al. (2012), we found that culturing HIV at
39.5 1C enhanced viral infectivity up to 30-fold in human peripheral blood mononuclear cells (p¼0.002)
and rescued CA-mutant infectivity in nonactivated cells, concurrent with elevated expression of
HSP90AB1 during hyperthermia. In sum, the transdominant effect of HSP90AB1 on CA-mutant HIV
infectivity suggests a potential role for this class of cellular chaperones in HIV core stability and
uncoating.
& 2012 Elsevier Inc. Open access under CC BY-NC-ND license. Introduction
The highly ordered proteolysis of HIV Gag is required for
condensation of capsid (CA) monomers into an intact and stable
core lattice (Wright et al., 2007). This sequential maturation
process prepares the HIV core for uncoating in the infected cell
(Vogt, 1996). Although the precise mechanism and location of HIV
uncoating are not currently known, the early postentry steps in
HIV infection are presumed to be regulated by host proteins,
including cyclophilin A and TRIM5a, in the infected cell (Goff,
2007; Luban et al., 1993; Stremlau et al., 2006).
Infectious HIV virions regularly display multiple and amor-
phously shaped cores (Carlson et al., 2008), and deviations from
optimal core stability often result in nonproductive infection (von
Schwedler et al., 2003). Through extensive mutational analysis of
the HIV CA, Forshey and colleagues described several key residues
that are crucial for intrinsic core stability and optimal virus
infectivity (Forshey et al., 2002). Recently, the same group
identiﬁed additional second-site suppressor mutations within
HIV CA that restore infectivity (Yang et al., 2012) but that,
surprisingly, do not alleviate the changes in core stability caused
by the original mutations. In an in vitro uncoating assay, the P38Apeptide 1; AChE, Acetylcho-
pha (cytosolic), class B
eldanamycin
ddart).
-NC-ND license. mutation rendered the HIV CA core unstable, but the E45A
mutation resulted in a hyperstable core. Yang et al. found that
introducing the T216I and R132T suppressor mutations in HIV CA
restored infectivity to both the P38A and the E45A mutant
viruses. Unexpectedly, the compensatory suppressor mutations
did not rescue the altered stability of the CA-mutant cores,
leading the authors to propose that while a stable core is a
prerequisite for successful uncoating, alternate mutations can
arise to preserve critical CA-host factor interactions.
In a previous report (Joshi and Stoddart, 2011), we observed
that drug-resistance mutations in HIV protease (PR) resulted in
virions harboring incompletely processed CA molecules with
uncleaved CA-spacer peptide 1 (CA-SP1). This apparent defect
greatly reduced PR-mutant HIV infectivity in nonactivated cells
and infectivity of the virus containing uncleaved CA-SP1 was
arrested before proviral DNA synthesis. The PR-mutant virus
displayed robust replication in activated cells, which suggested
that the cellular status of the target cell dictated the infectivity of
PR-mutant HIV. Through a functional genetic screen, we identi-
ﬁed heat shock protein 90 kDa alpha (cytosolic) class B member 1
(HSP90AB1) as a host factor that alleviated this block to infectiv-
ity in activated cells. The inﬂuence of HSP90AB1 was not
restricted to the defective CA-SP1 phenotype, as pharmacologic
inhibition (IC50¼0.1770.03 mM) of this cellular chaperone
decreased wild-type (WT) HIV infectivity.
In this report, we show that HSP90AB1 is incorporated into
virions but outside of the HIV core. The relevance of HSP90AB1
incorporation is currently under investigation, but here we extend
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HSP90AB1 can rescue the impairment imposed by mutations in
HIV CA. For this study, we selected mutations in CA that
recapitulate the CA-SP1 PR-mutant phenotype in that the
CA-mutant viruses are arrested after entry and before proviral
DNA integration. Consistent with rescue of the CA-SP1 PR-mutant
phenotype, the CA mutants infected phytohemagglutinin (PHA)-
activated human peripheral blood mononuclear cells (PBMC) and
unactivated Jurkat T cells expressing native HSP90AB1. Further,
the CA mutants were hypersensitive to pharmacological inhibi-
tion of HSP90AB1 compared to WT HIV. The expression of
HSP90AB1 responds to changes in ambient temperature and
consistent with a recent report by Roesch et al. (Roesch et al.,
2012), we found that raising the incubation temperature to
39.5 1C enhanced HIV infectivity up to 30-fold, concurrent with
an increase in HSP90AB1 expression. More importantly, CA-SP1
HIV and the panel of CA mutants were infectious in target cells
incubated at 39.5 1C.Fig. 1. HSP90AB1 is associated with HIV virions. (A) Western blot analysis of WT HIV vi
The puriﬁed pellet from mock- and WT HIV-transfected samples were probed for HSP9
independently puriﬁed cell culture supernatant preparations. (B) The sensitivity of the
detection of 0.78 U/ml of AChE was reliably achieved with these assay conditions. (C
cytoplasmic organelles and vesicles by assessing AChE activity. The positive control re
comparable volume of 293T-17 culture supernatant. The mean AChE Vmax7SEM for
represents one of three independent assays.Results
Cellular HSP90AB1 is associated with HIV virions
Mature HIV virions are known to incorporate cellular proteins, and
recent studies have identiﬁed a vast array of virion-associated host
proteins (Ott, 2008), so we therefore investigated whether HSP90AB1
was also associated with HIV virions. In general, cytoplasmic orga-
nelles, vesicles, and physiological nanoparticles are similar to envel-
oped retroviruses in terms of size and buoyant density (Cantin et al.,
2008). Due to these similarities, even carefully puriﬁed retrovirus
preparations are often contaminated with these nonviral cytoplasmic
organelles and vesicles. To ensure that HSP90AB1 is a bona ﬁde
cellular protein associated with HIV virions, we tested highly puriﬁed
virus preparations for the presence of this abundant cellular protein.
Previous studies have successfully described the use of iodixanol
velocity gradients to fractionate retrovirus preparations and have
shown that in vitro-generated HIV can be exclusively concentratedrions puriﬁed from transfected 293T-17 cell culture supernatant on 8.4% iodixanol.
0AB1 and alpha smooth muscle actin, and the results are representative of three
AChE assay was determined by serial-dilution of Electrophorus electricus AChE, and
) Pelleted virus and mock-transfected samples were assayed for contaminating
presents AChE activity in cytoplasmic organelles and vesicles sedimented from a
the positive control (293T-17 supernatant pellet) was 2.7170.41, and the graph
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et al., 2008; Dettenhofer and Yu, 1999). We ﬁrst puriﬁed virions from
the culture supernatant over a conventional 20% sucrose cushion. The
virus pellet was resuspended in saline and subjected to an additional
puriﬁcation on 8.4% iodixanol, and the contents of the virus prepara-
tion were assayed by western blot (Fig. 1A). The puriﬁed virus
preparation was also probed for alpha smooth muscle actin to rule
out any trace contaminating cellular debris. We detected the presence
of HSP90AB1 in this highly puriﬁed HIV preparation. To conﬁrm the
absence of contaminating cytoplasmic organelles and vesicles, we
tested the virus preparation for acetylcholinesterase (AChE) activity in
an enzyme assay (Ellman et al., 1961) with sensitivity extending
below 1 U/ml, as determined by using serial dilutions of Electrophorus
electricus AchE (Fig. 1B). The level of AChE activity in the iodixanol-
puriﬁed pellets from WT HIV and mock-transfected culture super-
natants was comparable to the substrate control (Fig. 1C). A previous
study by Gurer et al. also investigated the presence of different heat
shock proteins in virions and did not detect heat shock protein 90
(Gurer et al., 2002), but more recent studies have detected HSP90AB1
in puriﬁed virions using mass spectrometry (Chertova et al., 2006;
Santos et al., 2012). Our results demonstrate that HSP90AB1 is indeed
associated with HIV virions.
HSP90AB1 is incorporated into HIV virions but is not detected
in the core
Due to the nature of retrovirus assembly and release from the
plasma membrane, cellular proteins are associated with theFig. 2. HSP90AB1 is incorporated into HIV virions. (A) Subtilisin digestion of puriﬁed HIV
subtilisin for 18 h at 37 1C. Virions were recovered by centrifugation, lysed in SDS-PAGE lo
antibody cocktail. An equal volume of subtilisin-treated virus lysate was probed independe
not present in the core. Western blot analysis of puriﬁed intact virions and HIV cores recov
indicated HIV proteins. HIV genomic RNA was detected by RT-PCR. The results are repressurface or within different compartments of the virus. To deter-
mine the location of HSP90AB1 with respect to HIV virions, we
exploited the nonspeciﬁc activity of the bacterial subtilisin
protease (Fig. 2A). Subtilisin treatment strips the virions of sur-
face proteins, including the extracellular domain of the gp41
transmembrane protein (Devroe et al., 2005; Ott, 2009). We
incubated puriﬁed HIV with increasing subtilisin concentrations
overnight, and virions were recovered by iodixanol puriﬁcation.
The absence of surface gp41 indicates the effective protease
activity of subtilisin and the detection of HSP90AB1 in these virus
preparations indicates that this cellular protein is found within
virions.
In an attempt to further determine the location of HSP90AB1
in HIV virions, we subjected intact virus to brief detergent lysis
(Welker et al., 2000). Puriﬁed HIV was treated with Triton X-100
to strip off the virus envelope, exposing the core. The extracted
cores were extensively washed, and their protein composition
was compared to that of intact virions (Fig. 2B). Characteristic of
detergent-lysed virus (Welker et al., 2000), the extracted cores
lacked the presence of transmembrane gp41 and matrix (MA)
protein, and the integrity of the extracted cores was conﬁrmed by
the presence of their expected contents (i.e., reverse transcriptase
(RT), integrase (IN), CA p24, nucleocapsid (NC), and viral genomic
RNA). HSP90AB1 was not detected in the extracted core prepara-
tions, indicating that this cellular protein is packaged within the
lumen of HIV virions between the virus membrane and the core.
Due to the nature of this assay, it is not possible to determine
whether HSP90AB1 is physically associated with the virus innervirions. Iodixanol-puriﬁed virions were incubated with the indicated concentration of
ading buffer, and individual virus proteins were detected with a human anti-HIV IgG
ntly for HSP90AB1 and gp41. (B) HSP90AB1 is incorporated within HIV virions but is
ered from Triton X-100-treated intact virus probed individually for HSP90AB1 and the
entative of three independent iodixanol-puriﬁed virus and core preparations.
P. Joshi et al. / Virology 436 (2013) 162–172 165membrane, with MA, or with the HIV core. Afﬁnity-binding studies
between HSP90AB1 and HIV structural proteins are underway to
determine if HSP90AB1 is actively recruited into assembling
virions.
HSP90AB1 is present in virions produced from an HIV-inoculated
T-cell line and overexpression of HSP90AB1 does not inﬂuence its
incorporation
Host cellular proteins incorporated into the HIV virion vary
between different virus-producing cell types and different proce-
dures to generate infectious virus in the lab (Cantin et al., 1996;
Giroud et al., 2011; Tremblay et al., 1998). The presence of
HSP90AB1 was detected in virions produced from Jurkat E6-1
cells inoculated with WT HIV (Fig. 3A). The bona ﬁde presence of
HSP90AB1 in virions was conﬁrmed by the absence of AChE
activity in the sample. Also, the original association between
HIV infection and HSP90AB1 was identiﬁed in activated cells and
subsequently conﬁrmed in cells overexpressing this cellular
protein. To determine if overproduction of HSP90AB1 inﬂuences
the extent of its incorporation, we tested virions puriﬁed from
HIV-infected Jurkat E6-1 cells that were either nonactivated,
transduced with a retroviral vector intended to overexpress
exogenous native HSP90AB1, or activated with anti-CD3 and
-CD28 antibodies (Fig. 3B). In comparison to normal Jurkat E6-1
cell lysate, we observed an increase in HSP90AB1 protein in Jurkat
E6-1 cells expressing exogenous recombinant HSP90AB1 and in
Jurkat E6-1 activated with anti-CD3 and -CD28 antibodies (top
panel), but these elevated protein levels did not alter the amount
of HSP90AB1 incorporated into virions (lower panel). In addition,
virus infectivity was tested in the TZM-bl reporter cell line, and
we did not observe any signiﬁcant change in virus infectivity
produced from activated cells or HSP90AB1-overexpressing Jurkat
E6-1 cells (data not shown). We tried to knock down HSP90AB1
by siRNA to determine if lowering the host factor expression level
would affect its incorporation or alter HIV infectivity. Given that
the cytosolic HSP90 isoforms are constitutively expressed and
account for 1%–2% of all cellular proteins (Whitesell and
Lindquist, 2005), we were unable to effectively reduce HSP90AB1
expression in both, 293T-17 and Jurkat E6-1 cell lines without
causing permanent cell damage. Taken together, these results
demonstrate that HSP90AB1 is detected in multiple HIV prepara-
tions and, under the present assay conditions its incorporation is
not inﬂuenced by increased HSP90AB1 protein level in the cell.
CA-mutant HIV can infect activated human primary cells
Our initial study focused on mutations in HIV protease that
prevent the enzyme from completely processing the CA precursor,
resulting in virions with a substantial proportion of uncleaved
CA-SP1 molecules. This defect alone greatly reduced PR-mutant
infectivity; nevertheless, the PR-mutant virus was infectious in
PHA-activated PBMC. In this study, we sought to determine if
cellular activation could also rescue HIV with CA mutations that
reduce virus infectivity. HIV CA has been subjected to extensiveFig. 3. HSP90AB1 is incorporated into HIV virions collected from infected Jurkat E6-1
cells and is not altered by overexpression of recombinant HSP90AB1 or cellular
activation. (A) Western blot analysis of virions puriﬁed from WT HIV-inoculated
Jurkat E6-1 culture supernatant. The results are representative of three independently
puriﬁed virus preparations. (B) Jurkat E6-1 cells were either transduced by a
retroviral vector expressing recombinant HSP90AB1 or were CD3- and CD28-
activated for 24 h, subsequently infected with WT HIV, and cultured for 4 days.
The treated Jurkat E6-1 cells were lysed, and 1 mg of protein was probed for
HSP90AB1. Probing for alpha smooth muscle actin served as a loading control. HIV
virions were iodixanol-puriﬁed from the culture supernatant and probed for
HSP90AB1 and CA. The results are representative of three independent assays.mutational analysis with the intent to determine structurally and
functionally important residues and motifs responsible for opti-
mal core formation (Dismuke and Aiken, 2006; Forshey et al.,
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CA mutations that resulted in either unstable or hyperstable
HIV cores were selected and similar to the CA-SP1 phenotype,
infectivity of the CA-mutant viruses was arrested after entry but
before complete proviral DNA synthesis. The selected mutations
did not affect virion formation, endogenous RT activity, genomic
RNA packaging, or CA p24 production (Forshey et al., 2002).
The selected CA mutants were previously shown to reduce HIV
infectivity from 1.2- to 34-fold in a single-cycle infection assay
(von Schwedler et al., 2003), although these authors observed
variation in infectivity when the CA mutants were tested in a
transformed T-cell line continuous culture assay. We ﬁrst tested
the ability of these CA mutants to infect PHA-activated PBMC and
determined that the CA p24 concentrations of WT, PR-mutant,
and CA-mutant virus stocks were comparable, conﬁrming that
these mutations did not affect virus yield (Fig. 4). To quantify the
infectivity of CA mutants in PHA-activated PBMC, we opted for aFig. 4. CA-mutant HIV can infect PHA-activated PBMC. (Table) The yield of WT
and mutant virus was determined by p24 concentration for each stock virus.
Infectivity of the CA mutants was determined by TCID50 values derived from serial
half-log dilutions of each virus stock in quadruplicate wells of PHA-activated
PBMC (1105 cells/well) and calculated as a reciprocal of the dilution at which
50% of the wells contained detectable (Z50 pg/ml) HIV p24 measured by ELISA
7 days after inoculation. The results represent the mean value of three indepen-
dent titrations for each virus stock with no signiﬁcant deviation from the mean in
each triplicate assay (p¼1). (Western blot) Mutations in CA do not preclude
incorporation of HSP90AB1 into virions. Western blot analysis of WT and CA-
mutant virions puriﬁed from transfected 293T-17 cell culture supernatant. The
pelleted virus was probed for HSP90AB1, and 1 mg of 293T-17 protein lysate was
used as positive control. In addition, virus preparations were probed for CA, MA,
and nucleocapsid proteins. The results are representative of three independent
iodixanol-puriﬁed virus preparations.highly sensitive 50% endpoint dilution assay in which the infec-
tious titer is determined from serial half-log dilutions of the stock
virus. The selected CA mutants infected activated primary human
cells to the extent that an infectious dose could be accurately
calculated for each virus stock (Fig. 4). As observed previously
(von Schwedler et al., 2003), the variation in CA-mutant infectiv-
ity between a single-cycle infection assay and a spreading virus
infection assay can be attributed to delayed replication kinetics of
the mutant viruses. Nonetheless, these results suggest that CA-
mutant HIV can establish productive infection in activated cells
and is reminiscent of the signiﬁcantly increased infectivity of CA-
SP1 PR-mutant HIV in activated PBMC (Joshi and Stoddart, 2011).
To determine if mutations in CA or the CA-SP1 phenotype affect
incorporation of HSP90AB1 into virions, we assayed highly puriﬁed
virions harboring the different mutations (Fig. 4). Neither the CA-
SP1 phenotype nor the CA mutations appeared to alter incorpora-
tion of HSP90AB1 into virions. Consistent with previous reports,
the CA mutations did not block Gag processing, as evidenced by
detection of CA, MA, and NC (Forshey et al., 2002). The PR-mutant
HIV phenotype displayed the characteristic presence of CA-SP1
(p25) and uncleaved NC-spacer peptide 2 (p8).
CA-mutant HIV is rescued by and hypersensitive to in vitro inhibition
of HSP90AB1
Consistent with previous reports (von Schwedler et al., 2003;
Yamashita et al., 2007), the selected mutations in HIV CA reduced
productive infection of Jurkat E6-1 cells, but cellular expression of
HSP90AB1 compensated for the constraints imposed by these CA
mutations (Fig. 5A). At the end of a 12-day continuous culture
assay, CA-mutant infection of Jurkat E6-1 cells transduced with
native HSP90AB1 increased by 1.7-fold for CAE128AþR132A to 5.4-
fold for CAN139A over CA-mutant infection of nonactivated Jurkat
E6-1 cells (Table 1). The P38A and Q63AþQ67A CA-mutant
viruses are reported to have unstable cores, while the E45A and
E128AþR132A mutations resulted in greater numbers of hyper-
stable cores per virion. A signiﬁcant increase in infection was
observed in HSP90AB1-transduced Jurkat E6-1 cells for three of
the CA mutants irrespective of core stability. The N139A mutation
in CA displays a normal WT-like stable core and normal core
numbers per virion with no discernable defects in assembly,
maturation, or viral RNA packaging, yet this mutation impairs
HIV infectivity. N139A appeared to most beneﬁt from cellular
expression of HSP90AB1 and exhibited exponential growth with
the potential to establish a spreading infection. The R143A
mutation in CA reduces the number of cores per virion but
paradoxically results in a hyperstable core. As with the other CA
mutants, infectivity of the R143A mutant HIV increased in the
presence of HSP90AB1. In parallel, we included the PR-mutant
PRI54VþV82A HIV as a positive control to validate the rescue by
overexpression of HSP90AB1.
We ruled out the possible inﬂuence of retroviral-mediated
cellular upregulation in Jurkat E6-1 cells simultaneously trans-
duced with the same retroviral vector expressing the catalytically
defective HSP90AB1E42AþD88A mutant. Overexpression of the
nonfunctional HSP90AB1E42AþD88A mutant protein failed to
increase CA-mutant infectivity beyond the level observed in
nonactivated Jurkat E6-1 cells. In addition, to validate rescue by
native HSP90AB1, we tested the transduced Jurkat E6-1 cells for
expression levels of both the native and mutant HSP90AB1
(Fig. 5B, top panel). First, equal amounts of Jurkat E6-1 lysate
extracted from nonactivated HSP90AB1-transduced and mutant
HSP90AB1E42AþD88A-transduced cells were probed for HSP90AB1
and the FLAG epitope, and equal protein loading was conﬁrmed
by comparable detection of actin. Second, because direct probing
of Jurkat E6-1 cell lysates does not discriminate between
Fig. 5. Reduced infectivity of CA-mutant HIV is rescued by HSP90AB1. (A) Jurkat E6-1 cells transduced with retroviral vectors expressing native and mutant HSP90AB1
were inoculated with WT, PR-mutant, and CA-mutant HIV at a MOI of 0.05. Results are expressed as mean supernatant HIV p24 levels7SEM (error bars) and each
experiment represents independent transduction of Jurkat E6-1 cells followed by inoculation repeated three separate times. CA-mutant p24 levels in Jurkat E6-1/
HSP90AB1 were compared to Jurkat E6-1 (*po0.05, **po0.001, Student’s t test). (B) Western blot analysis of transduced Jurkat E6-1 cells to demonstrate comparable
expression of native and mutant HSP90AB1. (top panel) 1 mg of protein from transduced Jurkat E6-1 cell lysate was probed for HSP90AB1, FLAG, and alpha smooth muscle
actin. Comparable detection of alpha smooth muscle actin served as a loading control. (lower panel) Detection of HSP90AB1 in Jurkat E6-1 cell lysates does not
discriminate between endogenous protein and the protein contributed by vector-mediated exogenous HSP90AB1 expression. Transduced Jurkat E6-1 cell lysates were
immunoprecipitated with an anti-FLAG antibody and subsequently probed for HSP90AB1. The results are representative of three independent assays. (C) CA mutations
render HIV hypersensitive to pharmacological inhibition of HSP90AB1 in vitro. PHA-activated PBMC inoculated at a MOI of 0.001 with each CA-mutant were treated with
serial half-log dilutions of 17-AAG, and 50% inhibitory concentrations (IC50) were calculated after 7 days. The 50% cytotoxic concentration (CC50) of the drug was
determined by MTT assay in uninfected PBMC. The graph represents the mean IC507SEM (error bars) of three independent assays.
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transduced exogenous expression of native or mutant HSP90AB1,
we immunoprecipitated the exogenously expressed N-terminal
FLAG-tagged native and mutant HSP90AB1 from the cell lysates
using anti-FLAG afﬁnity gel (Fig. 5B, lower panel). Further, to
ensure the IP was not carried out under saturating conditions, the
Jurkat E6-1 cell lysate from the ﬁrst-round IP was subjected to
additional IP using fresh anti-FLAG afﬁnity gel and subsequently
probed for HSP90AB1. The absence of HSP90AB1 in the second-
round IP indicates that recombinant protein expression did not
saturate the anti-FLAG afﬁnity gel. Under these conditions, we
found comparable protein expression between the native- and
mutant HSP90AB1-transduced Jurkat E6-1 cells. Taken together,
these results conﬁrm the rescue of CA-mutant HIV by native
HSP90AB1 and rule out the possible inﬂuence of cellular side
effects resulting from retroviral transduction or protein over-
expression. To determine if inhibition of HSP90AB1 in activated
primary cells would adversely affect infectivity of the CA mutantsvariants, we determined the antiviral activity of 17-(allylamino)-
17-demethoxy-geldanamycin (17-AAG), a pharmacological inhibitor
of HSP90AB1 (Powers and Workman, 2007) (Fig. 5C). 17-AAG is an
analog of the naturally occurring benzoquinone ansamycin class of
antibiotics and speciﬁcally competes with cellular ATP for the
N-terminal nucleotide binding site in HSP90AB1. Similar to HIV
with the CA-SP1 phenotype, the CA mutants were also hypersensi-
tive to HSP90AB1 inhibition, suggesting a functional association
between this cellular protein and the HIV core.
Hyperthermia enhances HIV infection
Members of the heat shock protein family respond to variation
in ambient temperature and, Roesch et al. (Roesch et al., 2012)
recently reported that raising the culture temperature to 39.5 1C
enhances HIV replication, without changing the surface expression
of CD4 or other cell surface markers, or accelerating HIV fusion.
In our hands, the infectious titer of WT HIV was increased 30-fold
Table 1
Cellular expression of HSP90AB1 can rescue infection-impaired CA-mutant HIV.
Relative infectivity (%) to WT HIV
Virus Jurkat
E6-1
HSP90AB1 Fold-
increase
Hsp90AB1
E42AþD88A
Wild-type HIV 100 133711 1.3 8377
HIV PRI54VþV82A 1574 6973 4.6 1774
HIV CAP38A 671 2074 3.4 871
HIV CAE45A 571 2272 4.4 671
HIV CAQ63AþQ67A 571 2376 4.6 571
HIV CAE128AþR132A 2273 3873 1.7 3474
HIV CAN139A 1571 8178 5.4 1571
HIV CAR143A 1771 3773 2.1 1371
Relative infectivity of WT and mutant HIV in Jurkat E6-1/HSP90AB1 and Jurkat
E6-1/HSP90AB1E42AþD88A cells compared to WT HIV infectivity in Jurkat E6-1 cells
after 12 days of continuous culture. Results are expressed as mean infectivi-
ty7S.E. for three independent transduction experiments each performed in
triplicate.
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fold (Fig. 6A). We inoculated PBMC at 37 1C in duplicate and then
incubated the cells at 37 or 39.5 1C for the duration of the assay.
Elevated culture temperatures may affect cell growth and viability,
which in turn might inﬂuence the infectivity of WT and mutant
HIV variants. At the end of a 7-day titration assay, the absolute cell
number and viability of PBMC incubated at 39.5 1C were compar-
able to those observed at 37 1C (Fig. 6B). Incubation at 39.5 1C also
resulted in a mean 3.6-fold-increase in HSP90AB1 expression
(Fig. 6C) and, taken together, these results provide evidence that
hyperthermia enhances HIV infectivity.
We next assayed the CA-mutant panel in a single-cycle
infection assay to determine if the elevated temperature enhances
HIV infectivity in nonactivated cells. The TZM-bl luciferase repor-
ter cell line was inoculated with WT, PR-mutant, and CA-mutant
HIV at 37 1C, and duplicate cultures were subsequently incubated
at 37 and 39.5 1C for the duration of the assay. The infectivity of
WT HIV increased 2-fold at 39.5 1C and the PR-mutant and CA-
mutant HIV, although noninfectious at 37 1C, were able to infect
the heat-shocked reporter cell line (Fig. 6D). We conﬁrmed that
incubating the TZM-bl cell line at 39.5 1C did not affect viability or
absolute cell number (Fig. 6E). As observed for PBMC, incubating
the TZM-bl cell line at 39.5 1C resulted in a mean 2.8-fold-increase
in HSP90AB1 expression (Fig. 6F). Our observation that hyperther-
mia enhances WT HIV infectivity up to 30-fold suggests a
functional role for the heat-shock response in HIV infection. The
observation that reduced infectivity of the PR-mutant and CA-
mutant viruses was rescued under hyperthermic conditions
implies that hyperthermia may inﬂuence the early postentry
stage of the HIV life cycle.Discussion
HSP90AB1 is one of two cytosolic isoforms of the heat shock
protein 90 family of cellular chaperones (Pearl et al., 2008). Heat
shock protein 90 family members are some of the most conserved
proteins in the kingdom of life and with the exception of the
Archaea, all prokaryotes and eukaryotes express one or more
genes encoding heat shock 90 proteins (Taipale et al., 2010). Heat
shock protein 90 members are at the hub of protein homeostasis,
executing conformation-dependent protein maturation and reg-
ulating the deleterious effects of misfolded proteins during
embryogenesis and development (Richter and Buchner, 2011).
The heat shock protein 90 machinery operates as a multisubunit
complex on a wide array of ‘‘client’’ proteins to achieve theiractive conformation (Li et al., 2012). Further, heat shock protein
90 members appear to inﬂuence the genetic variation of organ-
isms in response to environmental stress (Jarosz and Lindquist,
2010).
We have previously shown that HSP90AB1 rescues the loss in
HIV infectivity caused by incompletely processed CA-SP1 and in
this report, we extend our initial ﬁndings to evaluate the rele-
vance of HSP90AB1 in WT and CA-mutant infectivity. Analysis of
highly puriﬁed HIV revealed that HSP90AB1 is incorporated
within virions and is located within the virion but outside of
the virus core. The nature and content of cellular proteins
incorporated into HIV virions vary greatly between different
susceptible cell types and also depending on the method of virus
production. To rule out a bias for HSP90AB1 incorporation into
HIV virions produced by transient transfection of the human
embryonic kidney-derived 293 T-17 transformed cell line,
HSP90AB1 was also detected in puriﬁed virions generated by
infecting the human leukemic T-cell-derived Jurkat E6-1 immor-
talized cell line. In addition, Jurkat E6-1 cells were either activated
or transduced to overexpress recombinant HSP90AB1 before
inoculation with WT HIV. Overexpression did not inﬂuence the
virion concentration of HSP90AB1, and biochemical assays are
underway to determine the relevance of the presence of
HSP90AB1 within the HIV virion.
Core stability determines the fate of HIV infection and mutations
in CA often lead to nonproductive infection. The PR and CA
mutations did not affect the yield of virus production and, when
tested in a serial-dilution titration assay, the CA mutants infected
activated human primary cells. In addition, the PR and CA mutations
did not prevent incorporation of HSP90AB1 or affect virion forma-
tion. The selected CA mutations result in unstable cores that rapidly
dissociate, hyperstable cores that resist disassembly, or cores with
WT-like characteristics (Forshey et al., 2002). Here, we show that
CA-mutant HIV with unstable, hyperstable, or WT-like cores can
productively infect target cells that express HSP90AB1. These
observations are in agreement with the second-site suppressor CA
mutation for which the T261I and R132T compensatory mutations
restored infectivity to CA mutants with both unstable cores and
hyperstable cores (Yang et al., 2012). Further, the CA-mutant viruses
were hypersensitive to HSP90AB1 inhibition irrespective of core
stability, suggesting a functional role for this class of cellular
chaperone in early postentry HIV infection.
Heat shock proteins respond to changes in ambient tempera-
ture (Nakai and Ishikawa, 2001; Wandinger et al., 2008), and a
recent report (Roesch et al., 2012) demonstrated that hyperthermia
enhances HIV infectivity. In accordance with this report, we ﬁnd
that elevating the incubation temperature to 39.5 1C enhanced WT
HIV infectivity, though we observed a more pronounced 30-fold-
increase in virus infection. More importantly, the elevated incuba-
tion temperature restored infectivity to a panel of viruses with
mutant CA. This rescue effect was observed in a continuous culture
assay and in a single-cycle infection assay with a concurrent
increase in cellular HSP90AB1 levels.
Of the six CA mutants studied, the N139A mutant virus
appeared to most beneﬁt from expression of HSP90AB1 in the
target cell as well as from increased temperature. The proposed
structural model for monomeric CA places the N139 residue
within helix 7, a ﬂexible linker region that connects the large N-
terminal domain to the smaller C-terminal domain of CA. The
N139A mutation does not affect core stability or morphology but,
because maturation of the HIV core occurs in preparation for
uncoating, mutations at this position might prevent access to
essential CA-interacting host factors in the infected cell. This is in
line with the view by Vogt (Vogt, 1996) in that ‘‘Teleologically,
one can think of proteolytic maturation of Gag and Gag–Pol
proteins as readying the virion for a new round of infection.
Fig. 6. Hyperthermia enhances HIV infectivity. (A) Comparison of WT, PR-mutant, and CA-mutant infectivity assayed at 37 and 39.5 1C was determined by TCID50 values derived
from serial half-log dilutions of each virus stock in quadruplicate wells of PHA-activated PBMC (1105 cells/well) and calculated as a reciprocal of the dilution at which 50% of
the wells contained detectable (Z50 pg/ml) HIV p24 measured by ELISA 7 days after inoculation. Results are represented as mean fold-increase in HIV infectivity at
39.5 1C7SEM for three independent titration experiments. (B) Flow cytometry analysis of PBMC cultures incubated at 37 and 39.5 1C for 7 days using the Trucount assay for
absolute PBMC cell number and amine aqua exclusion dye to determine cell viability. The ﬂow cytometry plots are one of three independent assays, and the mean total cell
number/ml7SEM was 11717470 for PMBC incubated at 37 1C and 11907501 for PBMC incubated at 39.5 1C. The mean percent cell viability7SEM was 6073 for PMBC
incubated at 37 1C and 6372 for PBMC incubated at 39.5 1C. (C) Hyperthermia increases cellular HSP90AB1 levels. Western blot analysis on 1 mg of protein from cell lysate
extracted from PBMC incubated at 37 1C and 39.5 1C for 7 days and probed for HSP90AB1 and alpha smoothmuscle actin. The mean fold-increase in HSP90AB1 expression7SEM
was 3.670.14, and the western blot represents one of three independent assays. (D) Comparison of WT, PR-mutant, and CA-mutant infectivity assayed at 37 1C and 39.5 1C in a
single-cycle infection assay. The TZM-bl luciferase reporter cell line was assayed for relative light units (RLU) 48 h after inoculation. The graph represents mean RLU7SEM (error
bars) from three independent inoculation assays. (E) Flow cytometry analysis of TZM-bl cultures incubated at 37 and 39.5 1C for 48 h using the Trucount assay for absolute cell
number and amine aqua exclusion dye to determine cell viability. The ﬂow cytometry plots are representative of three independent assays, and the mean total cell number/
ml7SEM was 223733 for TZM-bl cells incubated at 37 1C and 172743 for TZM-bl cells incubated at 39.5 1C. The mean percent cell viability7SEM was 9770.6 for TZM-bl
cells incubated at 371 C and 9670.8 for TZM-bl cells incubated at 39.5 1C. (F) Hyperthermia increases cellular HSP90AB1 levels. Western blot analysis of 1 mg of protein from
lysate extracted from TZM-bl cells incubated at 37 1C and 39.5 1C for 48 h and probed for HSP90AB1 and actin. The mean fold-increase in HSP90AB1 expression7SEM was
2.870.21, and the western blot represents one of three independent assays.
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dissociation in the newly infected cell and perhaps facilitating
reverse transcription of the genome.’’ The transdominant effects
of cell activation, HSP90AB1 expression, and increased tempera-
ture independently rescued the CA-mutant viruses, and further
analysis of the N139A mutant will determine if structural motifs
in or around this residue regulate HIV core uncoating in an
infected cell.In conclusion, altering the protein composition of the HIV core
most likely precludes essential host factors from facilitating the
postentry events of infection but despite that, nonlethal muta-
tions in virus structural proteins routinely occur in response to
immune pressure, evolutionary constraints, and drug therapy.
Detection of HSP90AB1 in HIV virions and the observation that
hyperthermia enhances virus infectivity suggest a functional role
for this cellular chaperone in the HIV life cycle. Further analysis
P. Joshi et al. / Virology 436 (2013) 162–172170will reveal if HSP90AB1 directly interacts with the HIV core or
if expression of this cellular chaperone in turn induces environ-
ment conducive suboptimally assembled virions to uncoat in an
infected cell.Material and methods
Cells, virus, and expression constructs
The following reagents were obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH: Jurkat clone E6-1 from Dr. Arthur Weiss (Weiss et al., 1984),
the TZM-bl cell line from Dr. John C. Kappes, Dr. Xiaoyun Wu and
Tranzyme Inc. (Derdeyn et al., 2000; Wei et al., 2002), and the
pNL4-3 infectious molecular proviral DNA clone from Dr. Malcolm
Martin (Adachi et al., 1986). The 293T-17 cell line was obtained
from the ATCC (Manassas, VA). pNL4-3 was transfected into 293T-17
cells using Lipofectamine2000 (Invitrogen) to generate WT, PR-
mutant, and CA-mutant HIV stocks. The 50% tissue culture
infectious dose (TCID50) of WT, PR-mutant, and CA-mutant stock
viruses was determined with serial half-log dilutions of each virus
stock in quadruplicate wells of PHA-activated PBMC (1105 cells
per well). The TCID50 was calculated as a reciprocal of the dilution
at which 50% of the wells contained detectable (Z50 pg/ml) HIV
p24 measured by ELISA (Perkin Elmer) 7 days after inoculation.
CA mutations were introduced individually into pNL4-3 by
standard site-directed mutagenesis (Agilent Technologies). The
I54V and V82A PR-mutant HIV clone has been described earlier
(Joshi and Stoddart, 2011). Native HSP90AB1 and catalytically
inactive mutant HSP90AB1E42AþD88A were cloned into a murine
leukemia virus (MLV)-based retrovirus expression vector, as
described earlier (Joshi and Stoddart, 2011).
Puriﬁcation of HIV virions
A subconﬂuent culture of 293T-17 cells was transfected with
the respective WT and mutant pNL4-3 clones for 4 h using
Lipofectamine2000 followed by a change of culture medium.
The supernatant was harvested 48 h later, clariﬁed by low-
speed centrifugation, and ﬁltered through a 0.22-mm membrane,
and virions were sedimented through a 20% sucrose cushion at
100,000 g for 2 h at 4 1C. The virus pellet was resuspended in
phosphate-buffered saline (PBS), treated with DNase (RNase-free,
Roche) and overlaid on 2 ml of 8.4% iodixanol (OptiPrep, Sigma).
HIV virions were sedimented at 100,000 g for 1.5 h, resus-
pended in PBS, and assayed for p24 content (Perkin Elmer). The
pelleted WT, PR- and CA-mutant samples were diluted to 10 mg
p24 per ml in PBS. Culture supernatant from mock-transfected
293T-17 cells was treated identically, and the resulting ‘‘pellet’’
was resuspended in the same volume of PBS as the virus samples.
Acetylcholinesterase activity assay
AChE activity was measured following a procedure described
previously by Ellman et al. (Ellman et al., 1961). Brieﬂy, 50 ml of
the iodixanol-puriﬁed HIV pellet was diluted to 100 ml in PBS and
mixed with 100 ml of 1.25 mM acetylthiocholine (pH 8) and
0.1 mM 5,5-dithio-bis(2-nitrobenzoic acid) (pH 7) in PBS.
The incubation was performed at room temperature, but the test
samples and the substrate solution were prewarmed to 37 1C for
10 min before reading the optical density. Changes in absorption
were monitored at 450 nm for 10 min with a plate reader
spectrophotometer. The sensitivity of the assay was determined
using serial dilutions of Electrophorus electricus AChE (Sigma). As a
positive control for AChE activity, cytoplasmic organelles andvesicles from a comparable volume of 293T-17 culture super-
natant were sedimented at 10,000 g for 1.5 h, and AChE activity
was determined in 50 ml of the resuspended pellet. The enzyme
kinetics (Vmax) of AChE in the iodixanol-puriﬁed HIV sample,
mock-transfected sample, and positive control were calculated
using the Michaelis–Menten protocol.Western blot analysis
The equivalent of 100 ng p24 from puriﬁed WT, PR-, and CA-
mutant preparations was resuspended in Laemmli SDS-PAGE
loading buffer (Sigma). Sample volume from the mock transfec-
tion was normalized to the virus preparations by loading the
same volume size as the puriﬁed WT HIV preparation. Cellular
protein from Jurkat E6-1 and 293T-17 cell lines was extracted
using the CelLytic M solution (Sigma), and protein concentration
was estimated using bicinchoninic acid (Sigma). High-molecular-
weight HIV proteins were separated on 8%–20% linear gradient
polyacrylamide gels and smaller HIV proteins were resolved on
15% gels. Cellular and HIV protein samples for the detection of
HSP90AB1 and alpha smooth muscle actin were resolved on a
stacked 12% polyacrylamide gel. The proteins were electroblotted
onto Immobilon PVDF membranes (Millipore) and reacted indi-
vidually with speciﬁc primary antibodies. The following primary
antibodies were obtained from the AIDS Reagent Program; CA
(cat. #6521), MA (cat. #4811), RT (cat. #11338), IN (cat. #7374),
gp41 (cat. #7623), and HIV-immunoglobulin (cat. #3957). The NC
primary antibody was obtained from the National Cancer Institute
AIDS Vaccine Program. Rabbit anti-HSP90AB1, mouse anti-alpha
smooth muscle actin primary antibodies, and peroxidase-
conjugated secondary antibodies were purchased from Abcam,
and immune complexes were visualized by enhanced chemilu-
minescence (Pierce).Subtilisin treatment of puriﬁed HIV
Virions from WT HIV-transfected 293T-17 cells were puriﬁed
as described above. The pelleted virus was resuspended in 500 ml
of 10 mM Tris pH 8.0, 100 mM NaCl and mixed with an equal
volume of 2 digestion buffer (40 mM Tris pH 8.0, 2 mM CaCl2)
containing the bacterial subtilisin protease (Sigma), as previously
described (Ott, 2009). Samples were incubated with a ﬁnal
concentration of 100 mg/ml or 500 mg/ml subtilisin at 37 1C for
18 h and reactions stopped by addition of 1 mM phenylmethyl-
sulfonyl ﬂuoride (PMSF) (Sigma) for 20 min at room temperature.
The samples were diluted in PBS, and the virus was puriﬁed on
8.4% iodixanol as described above. Pelleted virions were resus-
pended in SDS-PAGE buffer containing 1 mM PMSF.Isolation of HIV cores
Intact WT HIV virions were puriﬁed as described above, and the
cores were puriﬁed using a standard protocol (Welker et al., 2000).
Brieﬂy, the pelleted virus was resuspended in 100 ml of PBS and
mixed with an equal volume of 200 mM NaCl, 100 mM morpholi-
nepropanesulfonic acid (MOPS) (pH 7.0). Intact virions were lysed
by addition of Triton X-100 to a ﬁnal concentration of 0.5%, and the
HIV cores were recovered by centrifugation in a microcentrifuge
(16,000 g) for 8 min at 4 1C. The pelleted cores were washed three
times with 100mM NaCl, 50 mM MOPS (pH 7.0), resuspended in
SDS-PAGE buffer, and subjected to immunoblotting. Prior to resus-
pending the extracted cores in SDS-PAGE buffer, a small fraction of
the sample was subjected to RT-PCR to detect the gag gene
sequence by standard methods.
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E6-1 cells
A subconﬂuent culture of Jurkat E6-1 cells was inoculated with
WT HIV at a multiplicity of infection (MOI) of 0.5 and cultured for
4 days. Culture supernatant from HIV- and mock-inoculated
Jurkat E6-1 cells was sedimented on iodixanol and the sample
pellets were tested for AChE activity as described above.
Overexpression of HSP90AB1 in Jurkat E6-1 cells
The design and construction of a retroviral-based gene transfer
vector intended to express human HSP90AB1 preceded by a short
FLAG epitope has been described earlier (Joshi and Stoddart,
2011). Jurkat E6-1 cells were transduced with 0.1 MOI of the
retroviral vector carrying the native HSP90AB1 gene for 24 h. The
transduced cells were resuspended in fresh culture medium,
inoculated at a MOI of 0.5 with WT HIV, and cultured for an
additional 4 days. Simultaneously, Jurkat E6-1 cells were acti-
vated in the presence of anti-CD3 and anti-CD28 antibody-coated
magnetic beads as recommended by the manufacturer (Invitro-
gen) for 24 h. Activated cells were treated similar to the
HSP90AB1-transduced cells and four days after inoculation, the
Jurkat E6-1 cells were washed in PBS and lysed in CelLytic M
solution (Sigma). Simultaneously, virions were puriﬁed from the
cell-free culture supernatant as described above. Cellular and HIV
proteins were resuspended in SDS-PAGE buffer and subjected to
immunoblotting.
CA-mutant inoculation of HSP90AB1-expressing cells
Jurkat E6-1 cells were transduced at a MOI of 0.1 with retro-
viral vectors carrying the native HSP90AB1 gene and a catalyti-
cally inactive mutant of HSP90AB1E42AþD88A, as described
previously (Joshi and Stoddart, 2011). The transduced Jurkat
E6-1 cells were inoculated at a MOI of 0.05 with WT HIV and
CA-mutant HIV, and the PR-mutant HIV PRI54VþV82A served as a
positive control for rescue of reduced infectivity of the mutant
viruses. Productive infection and HIV growth kinetics were
observed over 12 days by measuring HIV p24 levels in the
supernatant by standard ELISA (Perkin Elmer). Overexpression
of both native HSP90AB1 and the catalytically inactive mutant
HSP90AB1E42AþD88A was compared on transduced Jurkat E6-1 cell
lysates by immunoblotting. Additionally, the cell lysates were
subjected to immunoprecipitation (IP) using the anti-FLAG M2
afﬁnity gel (Sigma) for 18 h at 4 1C. To ensure the IP was not
performed under saturating conditions, the cell lysate was sub-
jected to an additional IP with the anti-FLAG M2 afﬁnity gel. The
IP protein was immunoblotted and subsequently probed with
anti-HSP90AB1.
In vitro antiviral activity assay
Antiviral activity of 17-AAG (Sigma) was assayed in PHA-
activated PBMC as previously described (Joshi and Stoddart,
2011). Brieﬂy, PBMC were inoculated in bulk at a MOI of 0.001 of
each virus for 2 h, cells were washed, and 1105 cells in 100 ml
were seeded in triplicate wells of a 96-well plate. Wells were
treated with 100 ml of serial half-log dilutions of 17-AAG or with
medium alone, and supernatants were assayed at day 7 for p24 by
ELISA. Parallel cellular toxicity of the drug was determined on
uninfected cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tet-
razolium bromide (MTT) assay (Sigma) on day 7. The IC50 (50%
inhibition of virus replication) and CC50 (50% reduction in cell
viability) were calculated as the mean of three independent assays.PBMC hyperthermia conditions and assays
The difference in infectivity of WT, PR-mutant, and CA-mutant
stock viruses in PHA-activated PBMC cultured at 39.5 1C compared
to 37 1C was determined from TCID50 values, as described above.
To ensure the elevated temperature did not inﬂuence HIV adsorp-
tion or entry, the 2-h inoculation period was carried out at 37 1C,
after which duplicate plates were incubated at 37 and 39.5 1C for
the duration of the assay. Simultaneously, uninoculated PBMC
were cultured at 37 and 39.5 1C for 7 days and assayed for cell
viability and HSP90AB1 protein content by western blot as
described above. The absolute number of PBMC was determined
by ﬂow cytometry with Trucount tubes (BD Biosciences), and the
viability of the 7-day culture was estimated by adding amine aqua
(Invitrogen) exclusion dye. The fold-increase in HSP90AB1 expres-
sion was calculated using the ImageJ software (http://imagej.nih.
gov/ij/, 1997–2012).
TZM-bl hyperthermia conditions and assays
The difference in infectivity of WT, PR-mutant, and CA mutants
was determined in a single-cycle infection assay using the TZM-bl
HeLa CD4 cell line, as previously described (Wei et al., 2002).
Brieﬂy, 20,000 TZM-bl cells were seeded into 12-well plates in
duplicate and inoculated with 0.01 MOI of the WT, PR-mutant,
and CA-mutant stock viruses. To ensure the elevated temperature
did not inﬂuence HIV adsorption or entry, the 4-h inoculation
period was carried out at 37 1C, after which duplicate plates were
incubated at 37 and 39.5 1C for the duration of the assay. After
48 h, the cultured cells were washed with PBS, and the Bright-Glo
luciferase assay substrate and buffer (Promega) were added
directly to each well to lyse the cells. Following a 2-min incuba-
tion, the cell lysate was transferred to a black 96-well plate, and
luminescence was measured on a SpectraMax M2 plate reader
(Molecular Devices). Simultaneously, uninoculated TZM-bl cells
were incubated at 37 and 39.5 1C for 48 h and assayed for
HSP90AB1 protein content and cell viability, as described above.Acknowledgments
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